ArticlePharmaceutics2019
Microfluidics-Assisted Size Tuning and Biological Evaluation of PLGA Particles.
Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Data-driven and mechanistic modelling of PLGA nanoparticle formation in hydrodynamic flow focusing microfluidics.Lab on a chip · 2026Article
- Innovative Production of Diclofenac Sodium-Loaded Solid Lipid Nanoparticles by Membrane Nanoprecipitation: Evaluation of Encapsulation Efficiency and Photoprotection Ability.Pharmaceutical research · 2026Article
- Camptothecin-Bearing PEGylated Polypropylenimine Dendriplexes for Prostate Cancer Gene Therapy: Impact of Microfluidic Processing on Physicochemical Properties and Transfection.Pharmaceutics · 2026Article
- A review of organ-on-chip fabrication methods: From early developments to overcoming inert barriers.iScience · 2025Review
- Disease modifying biomaterials for modulating mechanical allodynia in a preclinical model of rheumatoid arthritis.Bioengineering & translational medicine · 2025Article
- Optimization of PLGA Nanoparticle Formulation via Microfluidic and Batch Nanoprecipitation Techniques.Micromachines · 2025Article
- Nanoparticles with curcumin and piperine modulate steroid biosynthesis in prostate cancer.Scientific reports · 2025Article
- Reprogramming the melanoma and immunosuppressive myeloid cells with esomeprazole-loaded PLGA nanoparticles.iScience · 2025Article
- Advances in PLGA-Based Drug Delivery Systems for Glioblastoma Treatment.International journal of nanomedicine · 2025Review
- Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin-expressing cancers.Science advances · 2024Article
- Immunomodulatory effect of PLGA-encapsulated mesenchymal stem cells-derived exosomes for the treatment of allergic rhinitis.Frontiers in immunology · 2024Article
- Rationalized design to explore the full potential of PLGA microspheres as drug delivery systems.Drug delivery · 2023Article
- Mechanistic Computational Modeling of Implantable, Bioresorbable Drug Release Systems.Advanced materials (Deerfield Beach, Fla.) · 2023Article
- Fabrication of PEG-PLGA Microparticles with Tunable Sizes for Controlled Drug Release Application.Molecules (Basel, Switzerland) · 2023Article
- Translating the Manufacture of Immunotherapeutic PLGA Nanoparticles from Lab to Industrial Scale: Process Transfer and In Vitro Testing.Pharmaceutics · 2022Article
- A Review of Microfluidic Experimental Designs for Nanoparticle Synthesis.International journal of molecular sciences · 2022Review
- The roadmap to micro: Generation of micron-sized polymeric particles using a commercial microfluidic system.Journal of biomedical materials research. Part A · 2022Article
- Industrial Scale Manufacturing and Downstream Processing of PLGA-Based Nanomedicines Suitable for Fully Continuous Operation.Pharmaceutics · 2022Article
- Optimisation of a Microfluidic Method for the Delivery of a Small Peptide.Pharmaceutics · 2021Article
- Ultrabright Green-Emitting Nanoemulsions Based on Natural Lipids-BODIPY Conjugates.Nanomaterials (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Polymeric particles made up of biodegradable and biocompatible polymers such as poly(lactic-co-glycolic acid) (PLGA) are promising tools for several biomedical applications including drug delivery. Particular emphasis is placed on the size and surface functionality of these systems as they are regarded as the main protagonists in dictating the particle behavior in vitro and in vivo. Current methods of manufacturing polymeric drug carriers offer a wide range of achievable particle sizes, however, they are unlikely to accurately control the size while maintaining the same production method and particle uniformity, as well as final production yield. Microfluidics technology has emerged as an efficient tool to manufacture particles in a highly controllable manner. Here, we report on tuning the size of PLGA particles at diameters ranging from sub-micron to microns using a single microfluidics device, and demonstrate how particle size influences the release characteristics, cellular uptake and in vivo clearance of these particles. Highly controlled production of PLGA particles with ~100 nm, ~200 nm, and >1000 nm diameter is achieved through modification of flow and formulation parameters. Efficiency of particle uptake by dendritic cells and myeloid-derived suppressor cells isolated from mice is strongly correlated with particle size and is most efficient for ~100 nm particles. Particles systemically administered to mice mainly accumulate in liver and ~100 nm particles are cleared slower. Our study shows the direct relation between particle size varied through microfluidics and the pharmacokinetics behavior of particles, which provides a further step towards the establishment of a customizable production process to generate tailor-made nanomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.